MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. We are currently focused on developing MDMA-assisted therapy as a breakthrough therapy for posttraumatic stress disorder (PTSD), with plans to submit for U.S. Food and Drug Administration (FDA) approval in 2023. The results of our successful, pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014 as a public benefit corporation, MAPS PBC prioritizes public benefit over profit. We are a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization that has been working for over three decades to develop medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS PBC is a distributed team that uses technology and periodic in-person gatherings to stay connected. We seek candidates who are comfortable with and skilled at remote work and collaboration.